Non-Hodgkin lymphoma survival statistics

Coronavirus (COVID-19)

We have created a central resources hub for Health Professionals which hosts all of our CRUK resources and further materials to help with managing the pandemic. We are updating the information as guidance changes. There is also a page specifically for patients on our about cancer hub.

Health Professional COVID-19 and Cancer Hub

Survival

Survive non-Hodgkin lymphoma for 10 or more years, 2013-2017, England and Wales

Age

Age that non-Hodgkin lymphoma survival is highest, 2009-2013, England

 

Improvement

Non-Hodgkin lymphoma survival in the UK has tripled in the last 40 years

 

78.4% of males survive non-Hodgkin lymphoma for at least one year. This falls to 63.7% surviving for five years or more, as shown by age-standardised net survival for patients diagnosed with non-Hodgkin lymphoma during 2013-2017 in England.[1] Survival for females at one year is 80.6% and falls to 68.1% surviving for at least five years. Survival for females is higher than for than for males at one year, and higher than for males at five years.

Non-Hodgkin Lymphoma (C82-C85), Age-Standardised One-, Five- and Ten-Year Net Survival, Adults (Aged 15-99), England, 2013-2017

The bar chart shows one- and five-year net survival and predicted ten-year net survival, with 95% confidence intervals.
 

Non-Hodgkin lymphoma survival continues to fall beyond five years after diagnosis. 51.8% of males and 58.1% of females are predicted to survive their disease for ten years or more, as shown by age-standardised net survival for patients diagnosed with non-Hodgkin lymphoma during 2013-2017 in England.[1]

See also

Find out more about the counting and coding of this data

Cancer survival statistics for common cancers in the UK

Hodgkin lymphoma survival statistics

References

  1. Office for National Statistics, Cancer survival by stage at diagnosis for England, 2019.

About this data

Data is for: England, 2013 - 2017, ICD-10 C82 to C85.

Survival statistics give an overall picture of survival and the survival time experienced by an individual patient may be much higher or lower, depending on specific patient and tumour characteristics.

Last reviewed:

Five-year survival for NHL (all subtypes combined) decreases with increasing age. Five-year net survival in men ranges from 84% in 15-39 year-olds to 43% in 80-99 year-olds for patients diagnosed with NHL in England during 2009-2013.[1] In women, five-year survival ranges from 86% to 42% in the same age groups.

Non-Hodgkin Lymphoma (C82-C85), Five-Year Net Survival by Age, England, 2009-2013

See also

Non-Hodgkin lymphoma incidence statistics by age

Non-Hodgkin lymphoma mortality statistics by age

Cancer survival statistics by age

Hodgkin lymphoma survival statistics

References

  1. Office for National Statistics. Cancer survival in England: adults diagnosed in 2009 to 2013 , followed up to 2014. Newport: ONS; 2015.
  2. Haematological Malignancy Research Network (HMRN). Personal communication, 2013.

About this data

Data is for: England, 2009-2013, ICD-10 C82-C85

Last reviewed:

As with most cancers, survival for NHL (all subtypes combined) is improving. Some of the increase is likely to be attributable to changes in the diagnosis, classification and registration of NHL, so interpretation of these trends should be undertaken with caution.

One-year age-standardised Open a glossary item net survival for NHL in men has increased from 49% during 1971-1972 to 80% during 2010-2011 in England and Wales – an absolute survival difference Open a glossary item of 30 percentage points.[1] In women, one-year survival has increased from 50% to 79% over the same time period (a difference of 30 percentage points). 

Non-Hodgkin Lymphoma (C82-C85), Age-Standardised One-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011

Five- and ten-year survival has increased by an even greater amount than one-year survival since the early 1970s. Five-year age-standardised net survival for NHL in men has increased from 30% during 1971-1972 to a predicted survival of 68% during 2010-2011 in England and Wales – an absolute survival difference of 39 percentage points.[1] In women, five-year survival has increased from 31% to 70% over the same time period (a difference of 39 percentage points).

Non-Hodgkin Lymphoma (C82-C85), Age-Standardised Five-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011

Five-year survival for 2010-2011 is predicted using an excess hazard statistical model

Ten-year age-standardised net survival for NHL in men has increased from 22% during 1971-1972 to a predicted survival of 62% during 2010-2011 in England and Wales – an absolute survival difference of 41 percentage points.[1] In women, ten-year survival has increased from 22% to 64% over the same time period (a difference of 42 percentage points). Overall, more than 6 in 10 people diagnosed with NHL today are predicted to survive their disease for at least ten years.

Non-Hodgkin Lymphoma (C82-C85), Age-Standardised Ten-Year Net Survival, Adults (Aged 15-99), England and Wales, 1971-2011

Ten-year survival for 2005-2006 and 2010-2011 is predicted using an excess hazard statistical model

See also

Non-Hodgkin lymphoma incidence trends over time

Non-Hodgkin lymphoma mortality trends over time

Cancer survival statistics for common cancers in the UK

Hodgkin lymphoma survival statistics

References

  1. Data were provided by London School of Hygiene and Tropical Medicine on request, 2014.

About this data

Data is for: England and Wales, 1971-2011, ICD-10 C82-C85

Last reviewed:

The most recent England-wide data for 2004-2006 showed NHL (all subtypes combined) three-year survival rates for men were significantly lower in the most deprived areas than in the most affluent (60% versus 65%). For women, the deprivation gap was not significant (61% versus 68%).[1] However, a similar study from Scotland for 1996-2000 did not find any significant differences in survival by deprivation.[2] Rates of emergency presentation with NHL were significantly higher in the most deprived areas than in the most affluent, a study of patients in England in 2006-2008 found;[3] however a previous study found socio-economic status did not appear to be associated with delays in NHL diagnosis.[4]

See also

Find out more about the counting and coding of this data

Non-Hodgkin lymphoma incidence statistics by socio-economic variation

Non-Hodgkin lymphoma mortality statistics by socio-economic variation

Cancer survival statistics by socio-economic group

Hodgkin lymphoma survival statistics

References

  1. Rachet B, Ellis L, Maringe C, et al. Socioeconomic inequalities in cancer survival in England after the NHS cancer plan. Brit J Cancer 2010;103:446-53.
  2. Shack LG, Rachet B, Brewster DH, et al. Socioeconomic inequalities in cancer survival in Scotland 1986-2000. Brit J Cancer 2007;97:999-1004.
  3. National Cancer Intelligence Network. Routes to Diagnosis, 2006-2008: NCIN information supplement. London: NCIN; 2012.
  4. Neal RD, Allgar VL. Sociodemographic factors and delays in the diagnosis of six cancers: analysis of data from the "National Survey of NHS Patients: Cancer". Brit J Cancer 2005;92:1971-5.

About this data

See source for ICD codes and other data specifics.

Last reviewed:

Five-year relative survival for non-Hodgkin lymphoma in men in England (55%) and Northern Ireland (55%) are below the average for Europe (57%). Wales (54%) is also below the European average but Scotland (58%) is similar to the European average.[1] Across the European countries for which data is available, five-year relative survival in men ranges from 33% (Bulgaria) to 69% (Iceland).[1]

Five-year relative survival for non-Hodgkin lymphoma in women in England (59%) is below the average for Europe (62%). Wales (60%), Scotland (62%) and Northern Ireland (64%) are similar to the European average.[1] Across the European countries for which data is available, five-year relative survival in women ranges from 44% (Bulgaria) to 79% (Iceland).[1]

Non-Hodgkin Lymphoma (C82-C85, Age-Standardised Five-Year Relative Survival, Adults (Aged 15+), European Countries, 2000-2007

Data consists of both observed and predicted 5-year relative survival. Where sufficient follow-up was not available for recently diagnosed patients the period approach was used to predict 5-year cohort survival.

Possible explanations for persistent international differences in survival include differences in cancer biology, use of diagnostic tests and screening, stage at diagnosis, access to high-quality care, and data collection practices.[1]

See also

Cancer diagnosis and treatment

Non-Hodgkin lymphoma incidence

References

  1. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5 - a population-based study. Lancet Oncol 2014;15:23-34

About this data

Data is for: 29 European countries, patients diagnosed in 2000-2007 and followed up to 2008, non-Hodgkin lymphoma (C82-C85).

Last reviewed:

Cancer stats explained

See information and explanations on terminology used for statistics and reporting of cancer, and the methods used to calculate some of our statistics.

Cancer stats explained

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, 2 Redman Place, London, E20 1JQ or

Donate online

We’re now on twitter.
Join the conversation and follow @CRUKHCPs for news, updates and opinion.

 @CRUKHCPs

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.